NASDAQ:XOMA XOMA Royalty (XOMA) Stock Price, News & Analysis $25.83 +0.02 (+0.08%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$25.84 +0.01 (+0.04%) As of 07/25/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About XOMA Royalty Stock (NASDAQ:XOMA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XOMA Royalty alerts:Sign Up Key Stats Today's Range$25.48▼$25.9350-Day Range$23.85▼$27.9052-Week Range$18.35▼$35.00Volume13,297 shsAverage Volume58,859 shsMarket Capitalization$309.19 millionP/E RatioN/ADividend YieldN/APrice Target$69.50Consensus RatingBuy Company Overview XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California. Read More XOMA Royalty Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreXOMA MarketRank™: XOMA Royalty scored higher than 80% of companies evaluated by MarketBeat, and ranked 211th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingXOMA Royalty has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageXOMA Royalty has only been the subject of 1 research reports in the past 90 days.Read more about XOMA Royalty's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for XOMA Royalty are expected to grow in the coming year, from ($1.41) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA Royalty is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA Royalty is -22.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA Royalty has a P/B Ratio of 3.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about XOMA Royalty's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted373.23% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XOMA Royalty has recently increased by 24,066.67%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXOMA Royalty does not currently pay a dividend.Dividend GrowthXOMA Royalty does not have a long track record of dividend growth. Sustainability and ESG3.0 / 5Environmental Score-0.22 Percentage of Shares Shorted373.23% of the float of XOMA Royalty has been sold short.Short Interest Ratio / Days to CoverXOMA Royalty has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XOMA Royalty has recently increased by 24,066.67%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentXOMA Royalty has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for XOMA Royalty this week, compared to 2 articles on an average week.Search Interest3 people have searched for XOMA on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, XOMA Royalty insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,293,460.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of XOMA Royalty is held by insiders.Percentage Held by Institutions95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about XOMA Royalty's insider trading history. Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA Royalty and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Stock News HeadlinesESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionJuly 14, 2025 | prnewswire.comXOMA Royalty to Buy Turnstone BiologicsJune 27, 2025 | marketwatch.comAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this marks the beginning of “Trump’s Great Gain,” a new crypto bull phase driven by emerging federal policies. He believes certain altcoins could turn $900 into $108,000 — and reveals everything in a new presentation.July 26 at 2:00 AM | Paradigm Press (Ad)Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...June 27, 2025 | gurufocus.comTurnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value RightJune 27, 2025 | globenewswire.comXOMA Preferred Shares Series A declares $0.539 dividendJune 18, 2025 | seekingalpha.comXOMA Corp - 8.375% DP PFD B declares $0.5234 dividendJune 18, 2025 | seekingalpha.comSee More Headlines XOMA Stock Analysis - Frequently Asked Questions How have XOMA shares performed this year? XOMA Royalty's stock was trading at $26.28 at the start of the year. Since then, XOMA stock has decreased by 1.7% and is now trading at $25.83. How were XOMA Royalty's earnings last quarter? XOMA Royalty Corporation (NASDAQ:XOMA) announced its quarterly earnings results on Tuesday, May, 13th. The biotechnology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.32. The biotechnology company had revenue of $15.91 million for the quarter, compared to analyst estimates of $6.75 million. XOMA Royalty had a negative net margin of 13.04% and a negative trailing twelve-month return on equity of 12.43%. How do I buy shares of XOMA Royalty? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of XOMA Royalty own? Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/13/2025Today7/26/2025Next Earnings (Estimated)8/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:XOMA CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees10Year Founded1981Price Target and Rating Average Price Target for XOMA Royalty$69.50 High Price Target$104.00 Low Price Target$35.00 Potential Upside/Downside+169.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.82 million Net Margins-13.04% Pretax Margin-19.85% Return on Equity-12.43% Return on Assets-4.85% Debt Debt-to-Equity Ratio1.18 Current Ratio5.54 Quick Ratio5.54 Sales & Book Value Annual Sales$28.49 million Price / Sales10.85 Cash FlowN/A Price / Cash FlowN/A Book Value$6.95 per share Price / Book3.72Miscellaneous Outstanding Shares11,970,000Free Float10,878,000Market Cap$309.19 million OptionableOptionable Beta0.93 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:XOMA) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredStrait of Hormuz = $100 Oil?Dow Drops 540 Points, Oil Soars Middle East conflict sends markets plunging, oil jumping 8.5%. Investors fl...The Oxford Club | SponsoredURGENT: Trump Could Buy 1,000,000 Bitcoins TOMORROW?According to one report, senior officials and crypto insiders recently discussed Bitcoin accumulation at the h...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Royalty Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share XOMA Royalty With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.